Mfd. by :- Pfizer (Fulfilled By : Magicine Pharma)
Magicine Pharma is registered with the Government Of NCT, India, Ministry Of Health in Government of Delhi, India, registration number DL-RAJ-122372 and as a wholesale distributor, department file No. 44208.
Brand Name:- Lorbrena
Generic Name:- Lorlatinib
Dosage Form:- Tablet
Packaging:- 30 tablets
Indication:- Lung cancer
Storage:- Store it at room temperature
Lorbrena (lorlatinib) tablets are used in the treatment of non-small cell lung cancer, which has spread in other areas of the body. This medication works by slowing or stopping the growth of cancer cells. This medicine is used in patients who have a certain type of abnormal anaplastic lymphoma kinase (ALK) gene. Lorlatinib is given when other medicines have stopped working. Your doctor will decide the exact and proper dosing schedule. Do not stop the use of medicine without taking permission from your doctor.
Lorlatinib is a kinase inhibitor that has shown in vitro activity against several genes and protein rearrangements, including ALK, ROS1, TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. The gene rearrangement of ALK is a genetic alteration that drives the development of non-small cell lung cancer in several patients. Lorlatinib single oral dose absorbed in 1 to 2 hours.
This medicine may cause some serious and unwanted side effects. Which requires immediate medical attention otherwise it can also lead to higher risk. Do not forget to discuss the risk and benefits of this medication with your doctor.
Trouble in breathing
Trouble in speaking
Difficulty in urination
Burning and tingling sensations
Note- please contact your doctor, if you experience any side effects.
Use this medicine as prescribed by your doctor. Do not take this medicine in the wrong way and make sure to take this medication according to your dosing schedule.
In case you missed a dose, immediately contact your doctor. Do not use extra medicine to double up for the missed dose.
Emergency medical treatment is required. Please contact your medical advisor in case of an overdose.
This medicine is used to treat lung cancer. Take this medicine orally with or without food once daily. Try to take this medicine at the same time to get the most benefits of it. This medication helps to stop the growth of cancer cells in the body. Swallow the whole tablet and do not crush or chew the tablet. Take this medicine as directed by your medical advisor. Your dosage is based on your medical condition, age, and response to the treatment. Do not take 2 doses to make up for the missed dose. If you vomit after taking the medicine, do not take another dose.
Before starting treatment with the Lorbrena tablet, do not forget to discuss your previous medical history with your doctor.
Use effective methods of contraception to prevent pregnancy while taking this medicine.
Children and adolescents
This medicine is not advisable for use in children and adolescents.
Lorbrena tablets shouldn’t be used by women who are pregnant. It is recommended that this medication should be avoided during pregnancy.
This medicine is not recommended for use in breastfeeding women unless it is necessary. Please consult your doctor.
A regular blood test is necessary during treatment with this medicine.
Tell your doctor if you have allergies
Share your previous medical history with your doctor.
Don’t forget to tell your doctor if you ever had an irregular heartbeat, depression, or high cholesterol.
Do not breastfeed while taking this medicine.
Do not take this medicine if you are pregnant.
This medicine may cause eye problems such as - change in vision, pain in the eyes.
Do not crush, chew, or break the medicine.
Not safe for pregnant women.
Do not drive if you experience any sign of dizziness.
Do not take 2 doses at the same time.
Q1. What is Lorbrena (Lorlatinib)?
Ans. This medication is used to treat non-small cell lung cancer. Which targets a protein in cancer cells and stops them from growing.
Q2. How does this medication work?
Ans. Lorlatinib is a reversible tyrosine kinase inhibitor. TKIs help to stop the growth of cancer cells. Lorlatinib blocks the abnormal ALK.
Q3. What are the common side effects?
Ans. Some common side effects are:- Fever, vomiting, blurred vision, anxiety, bleeding gums, body ache, fatigue, headache, weakness, skin rash, diarrhea.
Q4. How should I take this medicine?
Ans. Take this medicine orally with or without food. Follow your doctor’s dosing instructions and take this medicine according to your dosing schedule.
Q5. In what strength is it available?
Ans. It is available in the strength of 100mg.
Q6. What if I miss a dose?
Ans. In case you miss a dose try to take the medicine as soon as you remember or skip the dose and take your next dose according to your dosing schedule.
Q7. What should I avoid while taking this medicine?
Ans. Follow your doctor’s instructions for any restriction.
Q8. Can I drive after taking this medicine?
Ans. Do not drive if you experience any symptoms of dizziness because it may affect your ability to drive.
Q9. Can I take this medicine during pregnancy?
Ans. This medicine is not recommended for pregnant women.
Q10. Can I take this medicine during breastfeeding?
Ans. This medicine is not recommended for use in breastfeeding women unless it is necessary.
Q11. Can I consume alcohol while taking this medicine?
Ans. Interaction with alcohol is unknown. Please consult your doctor before consuming alcohol.
Q12. What are the storage conditions?
Ans. Store this medicine at room temperature.
Q13. What are the self-care tips?
Ans. Keep yourself hydrated and maintain good nutrition.
Interactions may change how your medication works and increase the risk for side effects. Discuss with your doctor about your previous medical history.
Severe renal impairment
Interaction with alcohol is unknown, please take permission from your doctor before consuming alcohol.
This medicine is contraindicated for concomitant use with strong CYP3A inducers.
Lorbrena tablets are not recommended for use in patients with a known allergy to lorlatinib.
This medicine is contracted in patients with known hypersensitivity to lorlatinib.